Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/152157
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Grape Resveratrol Increases Serum Adiponectin and Downregulates Inflammatory Genes in Peripheral Blood Mononuclear Cells: A Triple-Blind, Placebo-Controlled, One-Year Clinical Trial in Patients with Stable Coronary Artery Disease

AuthorsTomé-Carneiro, Joao CSIC; Gonzálvez, Manuel; Larrosa, Mar CSIC ORCID; Yáñez-Gascón, María J. CSIC; García-Almagro, Francisco J.; Ruiz-Ros, José A.; Tomás Barberán, Francisco CSIC ORCID ; García-Conesa, María Teresa CSIC ORCID ; Espín de Gea, Juan Carlos CSIC ORCID
KeywordsResveratrol
Coronary artery disease
Adiponectin
Plasminogen activator inhibitor type 1 (PAI-1)
Cardiovascular
Clinical trials
Issue DateFeb-2013
PublisherSpringer
CitationCardiovascular Drugs and Therapy 27(1): 37-48 (2013)
Abstract[Purpose] The grape and wine polyphenol resveratrol exerts cardiovascular benefits but evidence from randomized human clinical trials is very limited. We investigated dose-depending effects of a resveratrol-containing grape supplement on stable patients with coronary artery disease (CAD) treated according to currently accepted guidelines for secondary prevention of cardiovascular disease.
[Methods] In a triple-blind, randomized, placebo-controlled, one-year follow-up, 3-arm pilot clinical trial, 75 stable-CAD patients received 350 mg/day of placebo, resveratrol-containing grape extract (grape phenolics plus 8 mg resveratrol) or conventional grape extract lacking resveratrol during 6 months, and a double dose for the following 6 months. Changes in circulating inflammatory and fibrinolytic biomarkers were analyzed. Moreover, the transcriptional profiling of inflammatory genes in peripheral blood mononuclear cells (PBMCs) was explored using microarrays and functional gene expression analysis.
[Results] After 1 year, in contrast to the placebo and conventional grape extract groups, the resveratrol-containing grape extract group showed an increase of the anti-inflammatory serum adiponectin (9.6 %, p = 0.01) and a decrease of the thrombogenic plasminogen activator inhibitor type 1 (PAI-1) (−18.6 %, p = 0.05). In addition, 6 key inflammation-related transcription factors were predicted to be significantly activated or inhibited, with 27 extracellular-space acting genes involved in inflammation, cell migration and T-cell interaction signals presenting downregulation (p < 0.05) in PBMCs. No adverse effects were detected in relation to the study products.
[Conclusions] Chronic daily consumption of a resveratrol-containing grape nutraceutical could exert cardiovascular benefits in stable-CAD patients treated according to current evidence-based standards, by increasing serum adiponectin, preventing PAI-1 increase and inhibiting atherothrombotic signals in PBMCs.
DescriptionThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Publisher version (URL)http://doi.org/10.1007/s10557-012-6427-8
URIhttp://hdl.handle.net/10261/152157
DOI10.1007/s10557-012-6427-8
ISSN0920-3206
E-ISSN1573-7241
Appears in Collections:(CEBAS) Artículos

Files in This Item:
File Description SizeFormat
2013 resveratrol adiponectin CARD DRUG THER.pdf610,55 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

WEB OF SCIENCETM
Citations

135
checked on Dec 2, 2021

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.